Medrysone is a topical glucocorticoid applied ophthalmically for the treatment of various ocular inflammatory or allergic conditions. Medrysone is a corticosteroid used in ophthalmology.
- Mechanism
- Curator reviewed
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, the drug binds to the glucocorticoid receptor in the cytosol. This migrates to the nucleus and binds to genetic elements which cause activation and repression of the involved genes in the inflammatory pathway.
- Primary indication
- For the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.Curator reviewed · 4 structured indications
- Formula / weight
- C22H32O3 · 344.4877 g/mol (avg)
- First approval
- Canada, 1969 · United States, 2006
- Code names
- GSH 1043 · NSC-63278 · U-8471
- Brand names
Resolves to
GZENKSODFLBBHQ-ILSZZQPISA-NSMILES[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])C[C@H](C)C2=CC(=O)CC[C@]12CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Medrysone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account